26th Feb 2024 7:00 am |
RNS |
GSK announces positive EAGLE-1 headline results |
22nd Feb 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
21st Feb 2024 7:00 am |
RNS |
ViiV LAI superior to orals in adherence-challenged |
20th Feb 2024 9:01 am |
RNS |
Julie Brown - External Appointment |
19th Feb 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
15th Feb 2024 3:32 pm |
RNS |
Director/PDMR Shareholding |
15th Feb 2024 7:00 am |
RNS |
GSK completes acquisition of Aiolos Bio |
13th Feb 2024 4:45 pm |
RNS |
Director/PDMR Shareholding - Replacement |
13th Feb 2024 3:40 pm |
RNS |
Director/PDMR Shareholding |
13th Feb 2024 3:35 pm |
RNS |
Director/PDMR Shareholding |
13th Feb 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
6th Feb 2024 7:10 am |
RNS |
FDA accepts Arexvy filing for adults 50-59 at risk |
6th Feb 2024 7:05 am |
RNS |
Shingrix 18+ at risk China filing review accepted |
6th Feb 2024 7:00 am |
RNS |
GSK presents positive DREAMM-7 phase III data |
1st Feb 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
1st Feb 2024 3:00 pm |
RNS |
Total Voting Rights |
1st Feb 2024 7:00 am |
RNS |
Statement: Zantac (ranitidine) litigation |
31st Jan 2024 7:00 am |
RNS |
Final Results |
29th Jan 2024 7:05 am |
RNS |
EMA accepts Arexvy filing for adults 50-59 at risk |
29th Jan 2024 7:00 am |
RNS |
European Commission authorises Omjjara in the EU |
19th Jan 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
18th Jan 2024 5:00 pm |
RNS |
Holding(s) in Company |
17th Jan 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
17th Jan 2024 7:00 am |
RNS |
GSK completes sale of shares in Haleon plc |
16th Jan 2024 4:40 pm |
RNS |
GSK announces intention to sell shares in Haleon |
16th Jan 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
10th Jan 2024 7:00 am |
RNS |
Nucala approved in China for use in severe asthma |
9th Jan 2024 7:00 am |
RNS |
GSK enters agreement to acquire Aiolos Bio |
2nd Jan 2024 3:00 pm |
RNS |
Total Voting Rights |
21st Dec 2023 3:30 pm |
RNS |
Director/PDMR Shareholding |
20th Dec 2023 4:44 pm |
RNS |
Publication of EMTN Suppl.Prospcts |
18th Dec 2023 7:00 am |
RNS |
Jemperli plus Zejula Trial Meets Endpoint |
13th Dec 2023 3:30 pm |
RNS |
Director/PDMR Shareholding |
12th Dec 2023 7:00 am |
RNS |
Japan accepts Arexvy filing for at risk adults |
11th Dec 2023 7:00 am |
RNS |
Jemperli plus chemotherapy EU authorisation |
4th Dec 2023 3:02 pm |
RNS |
GSK publishes provisional 2024 dividend dates |
1st Dec 2023 3:00 pm |
RNS |
Total Voting Rights |
30th Nov 2023 9:00 am |
RNS |
Block Listing Application |
29th Nov 2023 3:23 pm |
RNS |
Holding(s) in Company |
27th Nov 2023 7:00 am |
RNS |
GSK announces positive DREAMM-7 headline results |